Prioritizing CD4 Count Monitoring in Response to ART in Resource-Constrained Settings: A Retrospective Application of Prediction-Based Classification by Azzoni, L et al.
Prioritizing CD4 Count Monitoring in Response to ART in
Resource-Constrained Settings: A Retrospective
Application of Prediction-Based Classification
Livio Azzoni1., Andrea S. Foulkes2., Yan Liu2, Xiaohong Li3, Margaret Johnson4, Collette Smith5, Adeeba
bte Kamarulzaman6, Julio Montaner7, Karam Mounzer8, Michael Saag9, Pedro Cahn10, Carina Cesar10,
Alejandro Krolewiecki10, Ian Sanne11, Luis J. Montaner1*
1Wistar Institute, Philadelphia, Pennsylvania, United States of America, 2University of Massachusetts, Amherst, Massachusetts, United States of America, 3 BG Medicine,
Waltham, Massachusetts, United States of America, 4 Royal Free Hampstead NHS Trust, London, United Kingdom, 5UCL Medical School, London, United Kingdom,
6University of Malaya, Kuala Lumpur, Malaysia, 7University of British Columbia, Vancouver, British Columbia, Canada, 8 Philadelphia FIGHT, Philadelphia, Pennsylvania,
United States of America, 9University of Alabama, Tuscaloosa, Alabama, United States of America, 10 Fundacio´n Hue´sped, Buenos Aires, Argentina, 11University of the
Witwatersrand, Johannesburg, South Africa
Abstract
Background: Global programs of anti-HIV treatment depend on sustained laboratory capacity to assess treatment initiation
thresholds and treatment response over time. Currently, there is no valid alternative to CD4 count testing for monitoring
immunologic responses to treatment, but laboratory cost and capacity limit access to CD4 testing in resource-constrained
settings. Thus, methods to prioritize patients for CD4 count testing could improve treatment monitoring by optimizing
resource allocation.
Methods and Findings: Using a prospective cohort of HIV-infected patients (n= 1,956) monitored upon antiretroviral
therapy initiation in seven clinical sites with distinct geographical and socio-economic settings, we retrospectively apply a
novel prediction-based classification (PBC) modeling method. The model uses repeatedly measured biomarkers (white
blood cell count and lymphocyte percent) to predict CD4+ T cell outcome through first-stage modeling and subsequent
classification based on clinically relevant thresholds (CD4+ T cell count of 200 or 350 cells/ml). The algorithm correctly
classified 90% (cross-validation estimate = 91.5%, standard deviation [SD] = 4.5%) of CD4 count measurements ,200 cells/ml
in the first year of follow-up; if laboratory testing is applied only to patients predicted to be below the 200-cells/ml threshold,
we estimate a potential savings of 54.3% (SD= 4.2%) in CD4 testing capacity. A capacity savings of 34% (SD= 3.9%) is
predicted using a CD4 threshold of 350 cells/ml. Similar results were obtained over the 3 y of follow-up available (n= 619).
Limitations include a need for future economic healthcare outcome analysis, a need for assessment of extensibility beyond
the 3-y observation time, and the need to assign a false positive threshold.
Conclusions: Our results support the use of PBC modeling as a triage point at the laboratory, lessening the need for
laboratory-based CD4+ T cell count testing; implementation of this tool could help optimize the use of laboratory resources,
directing CD4 testing towards higher-risk patients. However, further prospective studies and economic analyses are needed
to demonstrate that the PBC model can be effectively applied in clinical settings.
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Introduction
Successful maintenance and expansion of anti-HIV-1 therapy
programs in resource-limited settings is determined by multiple
factors, such as clinical thresholds to start antiretroviral therapy
(ART), drug access, trained personnel, and laboratory infrastruc-
ture. World Health Organization (WHO) guidelines for HIV-1
therapy in adults recommend initiation of anti-HIV-1 therapy
after CD4 count drops below 350 cells/ml, with a clear indication
to treat irrespective of clinical state if the CD4 count is below 200
cells/ml [1]. While the ideal monitoring of response to ART is dual
(virological monitoring with high-sensitivity PCR as the bench-
mark to assess viral suppression, and monitoring of ART-mediated
immune reconstitution via assessment of change in CD4 count [2–
4]), this level of monitoring is often unsustainable within national
health programs in resource-constrained settings because of the
cost and limitations of the healthcare system infrastructure [5–11].
Although development of viral resistance linked to ineffective
monitoring remains a concern in resource-poor settings, monitor-
ing of clinical response (i.e., initial weight gain) and immune
reconstitution (i.e., rise in CD4 cell counts) has been broadly used
as a primary tool to assess success of therapy: there is a direct
relationship between a lack of clinical response or a lack of a rise in
CD4 count and risk of developing or not recovering from
opportunistic infections. Indeed, WHO guidelines for patient
monitoring address the imbalance between increasing treatment
access and limited monitoring capacity by promoting therapy
success definitions such as frequency of patients with CD4 count
.200 cells/ml at 6, 12, and 24 mo after starting ART [1].
Despite the advent of newer, more cost-effective point-of-care
devices for CD4+ T cell count determination using peripheral or
capillary blood, the cost of laboratory-based CD4 count
determinations to determine disease progression, indication for
therapy, and response to ART remains high in terms of both
economic and human resources (i.e., the need for specialized
instrumentation and trained laboratory staff). Thus, numerous
attempts have been made to identify low-cost surrogate markers
that are widely available even in resource-limited settings, with the
intent of eliminating the need for such intense CD4 count testing
within resource/capacity-limited national HIV therapy programs
[12]. The WHO recommends the use of total lymphocyte count to
monitor untreated chronic HIV infection as a surrogate for disease
progression changes, recommending treatment for patients with
TLC,1,200 cells/ml [1]. While useful in the context of when to
start treatment, TLC and other surrogate markers have not been
shown to be useful in monitoring therapy response and/or
treatment failure [13–19]. To date, no strategy has been proposed
to reduce the need for CD4 testing after ART.
Using prediction-based classification (PBC) [20], a recently
described model-based approach that accommodates repeatedly
measured quantitative biomarkers for outcome prediction, we have
developed a prioritization strategy to monitor response to ART
based on baseline CD4 count, prospective white blood cell count
(WBCC), and lymphocyte percent (Lymph%) measurements. In
contrast to previous attempts focused on providing a direct
surrogate marker for CD4 count, our approach could be used to
direct limited healthcare resources to high-priority patients classified
below predetermined CD4 count thresholds of clinical significance.
Methods
Cohorts
Anonymized data (WBCC, Lymph%, and CD4 count) were
obtained from a cohort of 3,357 HIV-1-infected, ART-naı¨ve
individuals at the following clinical sites: Royal Free Hampstead
NHS Trust, London, UK (used to generate the prediction rule);
University of Alabama at Birmingham, Birmingham, Alabama,
US; Jonathan Lax Center, Philadelphia FIGHT, Philadelphia,
Pennsylvania, US; University of Malaya, Kuala Lumpur,
Malaysia; University of the Witwatersrand, Johannesburg, South
Africa; Fundacio´n Hue´sped, Buenos Aires, Argentina; and
University of British Columbia, Vancouver, British Columbia,
Canada, for a total of 32,974 cumulative observations. Individual
contributions from each site are summarized in Table 1.
Participants were repeatedly observed for up to 3 y after ART
initiation, and all patients had at least one post-initiation-of-ART
(baseline) assessment. There were no restrictions on initial CD4
count.
Primary analysis is focused on a subset of individuals (n = 1,956;
Cohort 1) with complete data, defined as having at least one
assessment (CD4+ T cell count, WBCC, and Lymph% measured
at the same time) and no more than six assessments in each 6-mo
period of follow-up—for 1 y after initiation of ART. Additionally,
we consider a subset of these individuals (n = 619; Cohort 2) with
complete data for 3 y of follow-up to assess the longer-term
feasibility of this strategy.
Statistical Analysis
We applied the PBC algorithm, which in brief involved fitting a
mixed-effects model to the repeated measures of CD4 counts and,
in turn, using model-derived estimates to define a prediction rule
for whether post-baseline (start of ART) observations would be
above predefined thresholds of 200 and 350 CD4+ T cells/ml.
Patients with values predicted to be below these thresholds would
be prioritized for actual CD4 testing. Algorithm performance
compared to an alternative generalized linear modeling approach
Table 1. Cohort description.
Cohort Site
Buenos Aires London Kuala Lumpur Philadelphia Johannesburg Birmingham Vancouver Total
Total 100 (542) 270 (2635) 35 (102) 72 (399) 1,351 (4,239) 66 (640) 1,463 (24,336) 3,357 (32,893)
Cohort 1 58 (217) 214 (1,375) 15 (45) 55 (223) 654 (2,058) 59 (292) 901 (5,985) 1,956 (10,195)
Cohort 2 15 (147) 49 (679) 0 (0) 5 (43) 0 (0) 32 (398) 518 (8,559) 619 (9,826)
Data are expressed as number of individuals (number of observations over time). Cohort 1 is composed of individuals with complete data—between one and six
assessments (CD4+ T cell count, WBCC, and Lymph% measured at the same time) within each 6-mo interval—for 1 y of follow-up. Cohort 2 is composed of individuals
with complete data for 3 y of follow-up.
doi:10.1371/journal.pmed.1001207.t001
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is detailed in Foulkes et al. [20] and includes improvements in
sensitivity, positive predictive value, and negative predictive value
for the same false positive rate (FPR). Briefly, the primary
advantages of PBC over alternative strategies are the following: (1)
PBC draws strength from the full range of continuous outcomes
(through application of a linear model) while offering clinically
relevant measures (such as positive and negative predictive value)
through subsequent classification; and (2) it incorporates simulta-
neously multiple, repeatedly measured biomarkers observed at
unevenly spaced intervals.
Formally, the PBC algorithm with cross-validation (CV) is given
as follows, with additional details and formal mathematical
derivations provided in Foulkes et al. [20]. Re-substitution
estimates were determined using the same algorithm detailed
below, with the full cohort used in place of both the learning and
test samples (i.e., removing steps 1 and 7).
PBC Algorithm
Step 1. We first randomly selected a learning sample
composed of approximately 90% of the individuals in the full
cohort to derive the prediction rule. Sample data included baseline
(defined as time of ART initiation) and repeated measurements of
CD4 count, WBBC, and Lymph% up to 3 y after ART initiation.
The remaining approximately 10% of individuals made up the test
sample.
Step 2. Based on the learning sample selected in step 1, we
fitted a mixed-effects change-point model to repeatedly measured
CD4 counts, with fixed effects for allowing different slopes before
and after 1 mo on ART, and random person-specific intercept
and slope terms (for time). The two time slopes are intended to
reflect the rapid rise in CD4 count during the first month after
ART initiation, and then the more gradual increase in CD4 over
the remaining observation time. Additional fixed-effects terms for
baseline CD4 count and baseline and time-varying WBCC and
Lymph% are included as predictor variables. Also included in the
model are fixed interaction effects between baseline CD4 count
and (1) time before and after the change point, (2) baseline and
time-varying values of WBCC, and (3) baseline and time-varying
values of Lymph%. All terms in the model have Wald test statistic
p-values of less than 0.10 for the complete cohort analysis, and
main effects are included when corresponding interaction effects
are statistically significant. Notably, application of a less stringent
level 0.10 test is appropriate at this stage given that the algorithm
additionally includes implementation of a CV procedure. Model
fitting is performed using the lme() function of the nlme package in
R version 2.11.1.
Step 3. Based on the model-based estimates derived in step 2,
we calculated predicted values of CD4 count for all post-baseline
observations in the learning sample. We also determined the lower
bounds of corresponding one-sided level-a prediction intervals for
a range of a values. Details about the calculation of these
prediction intervals, including derivation of the prediction
variance, as well as a discussion of their interpretation as
credible intervals are provided in Foulkes et al. [20]. For a given
a, the lower bound is denoted La,ij for the jth time point for
individual i. A new binary predicted response, denoted Yij,pred(a,K)
for the jth time point for individual i, is then defined as an
indicator for whether the corresponding lower bound is greater
than K where K = 200 or 350. That is, we let
Yij,pred(a,K)~
1 if La,ijwK
0 otherwise

ð1Þ
for each CD4 threshold K = 200 and 350. We selected 200 CD4+
T cells/ml as indicative of a risk of development of opportunistic
infections, and 350 CD4+ T cells/ml, the WHO-recommended
ART initiation threshold [1], defining high-priority patients (i.e.,
patients requiring laboratory-based testing) as those failing to
maintain CD4 counts above either of these thresholds after ART
initiation.
Step 4. Again based on the learning sample, we compared the
predicted variable Yij,pred(a,K) to an indicator for whether the
observed CD4 count is greater than K, which we denote Yij,obs(K),
where
Yij,obs(K)~
1 if CD4ijwK
0 otherwise

ð2Þ
and CD4ij is the observed CD4 count at the jth time point for
individual i. To measure a prediction rule for a given a level and
K, we calculated the FPR, defined as the proportion of post-
baseline observations that fall below the threshold Yij,obs(K)~0 but
are predicted to be above the threshold Yij,pred(a,K)~1 among
those observed to be below the threshold.
Step 5. The ‘‘optimal’’ prediction rule was defined for a given
threshold K as the rule (across all rules defined by the range of a
values) that maximizes the FPR in the learning sample, subject to
the constraint that the FPR is less than a predefined cut point.
FPR cut points of 5% and 10% were considered clinically relevant.
The a level corresponding to this optimal rule, denoted aoptimal,
was fixed for all subsequent analyses in the test sample.
Step 6. The test sample data were used to evaluate the
optimal prediction rule as follows. Baseline CD4 counts, time since
ART initiation, and baseline and post-baseline WBCC and
Lymph% were used as inputs in the model derived in step 2
above to arrive at predicted CD4 counts at all measured post-
baseline time points for individuals in the test sample. Notably, it is
assumed that post-baseline CD4 count is not observed in the test
sample, and so a correction for the empirical Bayes estimates from
the mixed model is required, as described in Foulkes et al. [20].
Corresponding lower bounds for one-sided level-aoptimal prediction
intervals were determined. Formally, this is denoted Laoptimal,ij for
the jth time point for individual i in the test sample. Binary
predictions for all post-baseline CD4 counts within the test cohort
were then defined according to Equation 1 where La,ij was
replaced with Laoptimal,ij . The dichotomized observed CD4 counts,
as given by Equation 2, were compared to these binary predictions
to arrive at the cross-validated estimates of sensitivity, specificity,
positive predictive value, negative predictive value, and capacity
savings. Capacity savings is defined as the ratio of tests spared by
use of the model (i.e., the number across all individuals of post-
baseline time points at which CD4 count is predicted to be above
the K threshold, and thus a CD4 test would not be performed,
divided by the total number of post-baseline time points).
Steps 1 to 6 are repeated ten times, and the average and
standard deviation (SD) of the estimates listed in step 6 are
reported as CV estimates. As these parameters are interdependent,
CV estimates are not consistently lower (or higher) than re-
substitution estimates using the full cohort. Copies of the R scripts
used are available at http://people.umass.edu/foulkes/software.
html.
Results
Cohort Description and Follow-Up
The geographical distributions of patients and corresponding
numbers of observations over time are summarized in Table 1. For
Prioritization Tool for CD4 Counts after ART
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Cohort 1, the median baseline (pre-ART) CD4 count was 145.5
cells/ml; 34% of the patients initiated ART with a CD4 count
.200 cells/ml, and 14.3% with a CD4 count .350 cells/ml.
Median baseline WBCC was 4.76103 cells/ml, and median
Lymph% was 30.7%. A detailed breakdown of these values for
each cohort is summarized in Table 2. Unlike Lymph% and
WBCC, median CD4 count and fraction of patients above 200 or
350 CD4+ T cells/ml were higher in the longer follow-up subset
(200 for Cohort 2, as compared to 139 for Cohort 1), possibly due
to the better clinical outcomes of patients that initiate treatment
with higher CD4 counts, as well as the longer average follow-up in
the London, Birmingham, and Vancouver cohorts. However, the
rate of ART responders, defined as patients who had a
documented CD4 raise of at least 20% from baseline over the
follow-up time, was similar across all cohorts. The overall response
to ART initiation was confirmed by the observed rise of median
CD4+ T cell count over the observation time, as illustrated in 6-mo
intervals in Figure 1 for the two cohorts.
PBC Application
The results of fitting mixed-effects change-point models (as
described in step 2 of the PBC algorithm) to Cohorts 1 and 2 are
given Table 3. The models suggest that the effects of WBCC,
Lymph%, and time (before and after 1 mo on ART) are modified
by baseline CD4 count (interaction terms are significant at the
0.10 level), and thus all main effects and interaction terms are
included in the final model. The model-based estimates (coefficient
estimates in Table 3) are used to derive the optimal prediction rule
(as described in steps 3–5 of the PBC algorithm) using maximum
FPRs of 5% and 10%. The results of applying the optimal rule to
Cohort 1 data are given in Table 4. Of the 8,239 post-baseline
observations, 5,976 (72.5%) had CD4 count .200 cells/ml, while
2,263 (27.4%) had CD4 count #200 cells/ml. Among observations
with CD4 count #200 cells/ml, the algorithm correctly classified
2,037 (90%; CV estimate = 91.5%, SD = 4.1%); the corresponding
FPR was 226/2,263 = 10% (CV estimate = 8.5%). Prioritized
CD4 testing would be recommended for all observations with a
predicted CD4 count ,200 cells/ml (n = 3,729; 45.5%). The
potential capacity savings based on this prioritization scheme,
where the likelihood of not detecting a low CD4 count (FPR) is
,10%, is 4,490/8,239 = 54.5% (CV estimate = 54.3%, SD =
4.2%). Alternatively, controlling the FPR at 5% would result in the
option to prioritize testing for more observations (n = 4,705;
57.1%) and would result in a capacity savings of 42.9% (CV
estimate = 44.4%, SD = 4.2%).
These results, as well as the results from applying a 350-cells/ml
threshold for CD4 count, are summarized in Figure 2 for both
cohorts. Additional details on cross-validated parameter estimates,
including sensitivity, specificity, negative predictive value, positive
predictive value, and capacity savings, as well as corresponding
SDs, are provided in Table 5 for both cohorts and thresholds.
Extending this analysis to Cohort 2 (inclusive of 3 y of follow-up)
resulted in overall similar capacity savings results, indicating that
the model is applicable for at least 3 y from ART initiation
without any intervening CD4 count assessment.
Application Examples and Test Cost Comparison
To illustrate the potential use of the model to provide individual
predictions, we applied our algorithm to six representative individ-
uals, selected from Cohort 2, based on initial CD4 count and the
availability of multiple assessments. In the patients tested (Figure 3),
the model performed well in prediction of a CD4 count.200 cells/ml
(green dots); in fact, it was always correct in these cases, whereas, as
expected, at some of the visits, patients predicted to have CD4 count
#200 cells/ml (red dots) actually had a CD4 count .200 cells/ml
(false negatives). As all cases predicted to be below threshold should be
tested using the traditional laboratory-based methods, real time
application of the model would not have exposed any of these patients
to an undetected dangerous CD4 count, while sparing 20 (57%) of
the 35 CD4 laboratory tests performed after baseline.
To assess the feasibility of the application of our modeling
scheme to a healthcare setting scenario, we compared cost
estimates for the PBC approach (at 200- and 350-cells/ml
thresholds) to the estimated costs of a high-cost CD4 testing
method (dual platform assessment) and a low-cost alternative
(Guava platform, Millipore) as applied to a constrained-resource
setting (South Asia). The details of this comparison are reported in
Table S1. Briefly, according to our literature-based cost estima-
tions, the PBC approach (considering a single initial laboratory-
based CD4 assessment, followed by PBC application with a
complete blood count performed for each individual, and CD4
assessment only for individuals predicted to have below-threshold
CD4 values) could result in test cost savings when complete blood
count cost is below ‘‘breakeven points’’ ranging from US$10.90
(PBC with 200-cells/ml threshold, CD4 laboratory testing based on
dual platform assessment) to US$1.38 (PBC with 350-cells/ml
threshold, Guava-platform-based laboratory CD4 testing). Impor-
tantly, the estimated cost of PBC (US$0.80) is well below all of
these thresholds, suggesting that the PBC method may prove to be
a cost-effective treatment monitoring strategy in future cost-
effectiveness analyses.
Discussion
We demonstrate that after obtaining a baseline WBCC and
Lymph% and one laboratory-based CD4+ T cell assessment, the
Table 2. Baseline characteristics.
Cohort CD4 Count (Cells/ml) Lymph% WBCC (Cells610
3/ml)
Median IQR
Percent CD4
Counts.200
cells/ml
Percent CD4
Counts .350
cells/ml
ART
Respondersa Median IQR Median IQR
Total 139.0 49.0, 238.0 31.3 12.7 30.0 21.7, 38.5 4.7 3.6, 6.0
Cohort 1 145.5 60.0, 250.0 34.0 14.3 93.1 30.7 23.0, 38.9 4.7 3.7, 6.0
Cohort 2 200.0 80.5, 340.0 48.6 22.9 97.4 31.7 23.3, 40.0 4.6 3.7, 5.8
aPercent of patients with one or more post-baseline visits with CD4 count .1.26baseline CD4.
IRQ, interquartile range (25th percentile, 75th percentile).
doi:10.1371/journal.pmed.1001207.t002
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response to ART can be monitored relying on relatively low-cost
clinical laboratory tests (i.e., WBCC and Lymph%) by using the
PBC approach. This method enables us to predict whether CD4+
T cell count remains above predetermined safety thresholds with
an estimated cross-validated FPR of 8.5%, and could potentially
lead to testing capacity savings as compared to monitoring
approaches based solely on repeated laboratory-based CD4 tests.
Given the high economic and capacity cost of laboratory-based
CD4 assessments [21,22], and the limited number of available
accredited laboratories [23,24]—circumstances that tax already
stretched health systems as they implement national HIV
treatment programs—a number of surrogate assessments (e.g.,
TLC) have been proposed to assess when HIV-infected patients
require treatment, and to monitor them while they are undergoing
treatment [12,13,15,16,25,26]. Since to date these surrogates have
not performed as well as CD4 counts in monitoring response to
ART [13–19], two other options are open to improve current
capacity utilization: (1) reducing the economic and human
resource cost of performing laboratory-based CD4 tests, and/or
(2) optimizing the use of existing resources to test only patients who
are likely to need testing (i.e., patients likely to have dangerously
low CD4 counts). The use of approaches that allow triaging
patients at highest risk (e.g., patients who are failing treatment) for
laboratory-based CD4 testing is expected to be particularly
beneficial in resource-constrained settings characterized by high
testing volume requirements (e.g., expanding treatment programs
in sub-Saharan Africa).
Based on this premise, we conceived an algorithm that is
intended as a triage/prioritization tool. To ensure the reasonable-
ness of the approach, we fixed the acceptable FPR at 0.05 or 0.1.
Although minimizing the FPR is desirable, there is an inevitable
trade-off between the FPR and capacity savings. We believe that
this error rate (5%–10%) is acceptable in light of the intrinsic
variability of laboratory-based CD4 testing, and therefore
clinically relevant.
Notably, erroneously predicting a CD4 count to be below 200
or 350 cells/ml when it is above this level (12sensitivity) is less
relevant to patient safety, as CD4 testing is recommended on
predicted failures, thus eliminating the risk associated with this
form of misclassification.
Our testing and validation indicate that the proposed model
worked well over the 3-y follow-up time in our dataset. The
possibility that periodic laboratory-based CD4 testing (e.g., every
year) would improve and/or extend the predictive life of the
model, to the point that it could be used continuously after ART
initiation, remains open, as its determination will require
dedicated prospective studies.
Our comparison of CD4 testing cost estimates indicates that the
use of the PBC strategy is anticipated to result in a potential
capacity and possibly cost savings at all the threshold levels
Figure 1. Distribution of CD4 count. The distribution of CD4 count at 6-mo time intervals was assessed for both Cohort 1 (left) and Cohort 2
(right). Means were calculated for patients with multiple CD4 count assessments in the same interval.
doi:10.1371/journal.pmed.1001207.g001
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assessed (Table S1). Further prospective healthcare economic
studies modeling primary data (inclusive of all monitoring costs)
obtained in target countries will be required to perform a net cost
comparison, formally assessing the ramifications of the application
and limitations of PBC testing for individual countries/regions’
testing capacity, as well as long-term cost per outcome. While such
studies are beyond the scope of this article, the data presented here
provide a strong rationale for such studies.
Notably, the model-derived estimates and predictive rule are
first derived based on application of PBC to a large cohort, as
described in this article. Through development of publicly
accessible web-based tools that incorporate the results presented
herein, the above-described scenarios can be applied to single-case
analyses. Additional contributions to this data resource will likely
allow for further model refinement and improvements in
predictive performance.
Table 4. Observed and predicted values resulting from application of PCB to Cohort 1.
Predicted Value Observed CD4 Count .200 cells/ml Observed CD4 Count ,200 cells/ml Total
Predicted CD4 .200 4,264 (51.7%) 226 (2.7%) 4,490 (54.5%)
Predicted CD4,200a 1,712 (20.8%) 2,037 (24.7%) 3,749 (45.5%)
Total 5,976 (72.5%) 2,263 (27.5%) 8,239 (100%)
Data are expressed as number of observations (percent of total).
aPrioritized CD4 testing recommended for this group.
doi:10.1371/journal.pmed.1001207.t004
Table 3. Mixed-effects change-point modeling results for Cohort 1.
Cohort Variable Coefficient Estimate Standard Error t-Value p-Value
Cohort 1 (Intercept) 266.212 22.817 22.902 0.004
Baseline CD4 (BL_CD4) 1.011 0.101 10.053 0.000
Time (in months) 37.424 19.331 1.936 0.053
[Time21]+a 228.515 19.419 21.468 0.142
Baseline Lymph% (BL_Lymph%) 20.119 0.318 20.374 0.708
Baseline WBCC (BL_WBCC)b 19.247 16.466 1.169 0.243
Lymph% 2.012 0.212 9.484 0.000
WBCCb 117.441 12.326 9.528 0.000
BL_CD4*BL_Lymph% 20.008 0.001 25.662 0.000
BL_CD4*BL_WBCC 20.521 0.066 27.899 0.000
BL_CD4*Lymph% 0.007 0.001 8.635 0.000
BL_CD4*WBCC 0.282 0.044 6.357 0.000
BL_CD4*Time 0.139 0.079 1.745 0.081
BL_CD4*[Time21]+ 20.148 0.080 21.850 0.064
Cohort 2 (Intercept) 264.254 48.206 21.333 0.183
Baseline CD4 (BL_CD4) 0.890 0.221 4.031 0.000
Time (in months) 63.075 39.389 1.601 0.109
[Time21]+a 256.659 39.409 21.438 0.151
Baseline Lymph% (BL_Lymph%) 20.730 0.672 21.086 0.278
Baseline WBCC (BL_WBCC)b 246.320 47.386 20.977 0.329
Lymph% 2.245 0.253 8.865 0.000
WBCCb 152.095 17.088 8.901 0.000
BL_CD4*BL_Lymph% 20.005 0.002 22.111 0.035
BL_CD4*BL_WBCC 20.272 0.140 21.950 0.052
BL_CD4*Lymph% 0.003 0.001 3.832 0.000
BL_CD4*WBCC 0.233 0.056 4.139 0.000
BL_CD4*Time 0.320 0.189 1.691 0.091
BL_CD4*[Time21]+ 20.332 0.189 21.756 0.079
a[Time21]+ indicates the positive component of [Time21], given as follow-up time after the first month for Time .1 mo, and 0 for Time #1 mo.
bWBCC is scaled by (divided by) a factor of ten.
doi:10.1371/journal.pmed.1001207.t003
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Table 5. Re-substitution and CV counts and estimates for the PBC model.
Cohort Ka FPRb Observed CD4 Count.K Observed CD4 Count,K Sensitivityc Specificityc,d PPVc NPVc
Capacity
Savingsc
Predicted
.K
Predicted
,K
Predicted
.K
Predicted
,K
1 200 0.10 4,264 1,712 226 2,037 0.71 (0.73; 0.048) 0.90 (0.92; 0.041) 0.95 (0.96;
0.020)
0.54 (0.57;
0.051)
0.54 (0.54;
0.042)
0.05 3,421 2,555 113 2,150 0.57 (0.60; 0.050) 0.95 (0.95; 0.031) 0.97 (0.97;
0.018)
0.46 (0.49;
0.041)
0.43 (0.44;
0.042)
350 0.10 2,348 1,094 478 4,319 0.68 (0.73; 0.044) 0.90 (0.89; 0.036) 0.83 (0.82;
0.048)
0.80 (0.82;
0.034)
0.34 (0.37;
0.039)
0.05 1,908 1,534 239 4,558 0.55 (0.58; 0.064) 0.95 (0.94; 0.032) 0.89 (0.88;
0.057)
0.75 (0.76;
0.043)
0.26 (0.27;
0.039)
2 200 0.10 5,234 2,548 142 1,283 0.67 (0.71; 0.050) 0.9 (0.88; 0.087) 0.97 (0.97;
0.022)
0.33 (0.35;
0.053)
0.58 (0.62;
0.048)
0.05 3,998 3,784 71 1,354 0.51 (0.53; 0.072) 0.95 (0.95; 0.043) 0.98 (0.98;
0.015)
0.26 (0.27;
0.041)
0.44 (0.46;
0.065)
350 0.10 2,993 2,402 381 3,431 0.55 (0.55; 0.048) 0.90 (0.90; 0.034) 0.89 (0.89;
0.026)
0.59 (0.58;
0.048)
0.37 (0.37;
0.050)
0.05 2,147 3,248 188 3,624 0.4 (0.41; 0.046) 0.95 (0.95; 0.027) 0.92 (0.92;
0.031)
0.53 (0.52;
0.049)
0.25 (0.26;
0.041)
aK: CD4+ T cell count threshold (cells/ml).
bFPR, assigned.
cRe-substitution estimate (mean CV estimate; SD of cross-validated estimates).
dFixed, as determined by FPR.
NPV, negative predictive value; PPV, positive predictive value.
doi:10.1371/journal.pmed.1001207.t005
Figure 2. Summary of model performance. (A) Cross-validated estimates of FPRs. The bars represent the number of observed post-baseline
observations below the thresholds indicated on the x-axis and at the indicated FPRs for Cohort 1 (left) and Cohort 2 (right). The dark shading indicates
the number of observations correctly identified for laboratory-based CD4 testing (i.e., CD4 counts predicted to be and observed to be below
threshold); lighter shading represents false positives (CD4 count incorrectly predicted as above threshold); cross-validated estimates of the FPRs are
indicated above each bar. (B) Capacity savings (CS) estimates. Dark shading indicates the number of observations in Cohort 1 (left) and Cohort 2
(right) predicted to require laboratory-based CD4 testing (i.e., CD4 count predicted to be below threshold), and light shading the number of
observations predicted to not require laboratory testing (i.e., CD4 count predicted to be above threshold) at the CD4 count threshold and FPR
indicated below each bar.
doi:10.1371/journal.pmed.1001207.g002
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Applications
In light of the considerations discussed above, our PBC-based
tool could be useful in a number of scenarios.
Prioritization/triage of CD4+ T cell count testing at the
laboratory level. In this case, a laboratory receiving a request
for blood differential and CD4 count would first perform the
differential, which requires limited time and commonly available
resources; using the information obtained from this differential
(WBCC and Lymph%), as well as the historic pre-ART baseline
CD4 count (either stored or provided by the clinic), the laboratory
could then run the prediction algorithm, and proceed to test only
those patients who are predicted to have a CD4 count below a
predetermined threshold.
Expansion of ART response monitoring at the clinic
level. Due to cost limitations, some rollout programs allow only
limited CD4 testing (e.g., every 6 mo). If ART-treated patients are
additionally monitored at the rollout clinics for clinical visits and
ART medication refills (e.g., every 3 mo), all patients could be
monitored at these ‘‘non-CD4’’ visits for ART response by drawing
a blood sample for a blood differential. Once the WBCC and
Lymph% results are obtained from the laboratory, the clinic could
employ the prediction tool to predict whether or not the patient’s
CD4 count is below a clinically meaningful threshold. Based on this,
patients who are predicted to be failing treatment can be counseled
for adherence, and/or further monitored by requesting a CD4
count. Because of the anticipated wider availability of complete
blood count testing as compared to CD4 testing, this approach may
result in shorter result turnaround time, partially reducing the acute
need for point-of-care CD4 testing [27].
Reduction of confirmatory CD4 tests. Due to the intrinsic
variability of current CD4 count tests, in many circumstances
laboratory-based CD4 tests yield unexpected or doubtful results
that are not in keeping with clinical observations (e.g.,
unexpectedly low CD4 count in a patient with increasing
WBCC, lymphocytes, hemoglobin, or weight, and controlled
viral load). In such cases, the CD4 count test may need to be
repeated for confirmation before any clinically relevant action is
taken (e.g., adherence counseling or regimen alteration and
resistance testing). The use of the PBC method to independently
confirm unexpected laboratory-tested CD4 counts could limit the
need for repeated CD4 measures.
As indicated throughout this section, our conclusions should be
tempered by considering some of the limitations of this work. First,
this work is not intended to provide a complete analysis of the
economic and healthcare outcomes of the application of PBC.
Future prospective studies based in actual resource-constrained
settings will be required to demonstrate the feasibility of this
approach; here we focus on providing the foundation and
rationale for such studies, which will be required to assess whether
or not implementation of a PBC-based monitoring approach is a
viable alternative to repeated CD4 testing. Second, it remains to
be assessed how long this approach can be extended in time, e.g.,
by adding periodic CD4 testing, and whether or not periodic viral
load testing would improve clinical outcomes of PBC-based
monitoring. Third, PBC requires specifying an acceptable FPR.
While the assessed rate can be lower, depending on the threshold
used, the fact remains that the PBC has an intrinsic, small
possibility of error. In light of the wide variability of CD4 count
testing results, we do not consider this to be problematic, but it’s
possible that the collection of additional data (and possibly the
introduction of other parameters, such as trends over time, into the
model) might improve the model fit and improve its accuracy, and
should be considered in future study design.
Finally, it is important to remark that the PBC-based method is
not intended to substitute for laboratory-based CD4 testing, not to
establish a ‘‘second tier’’ of healthcare standard to be applied to
developing countries. Rather, we propose that this method is a
potentially useful ‘‘triage’’ tool to direct available laboratory testing
capacity to high-priority patients. As a tool to optimize the use of
existing resources, the implementation of our PBC-based method
would be most beneficial in settings where laboratory resources are
currently limiting due to funding, human resources, or structural
limitations.
Conclusion
We propose a noninvasive, rapid turnaround method that could
be applied to predict CD4 failure (i.e., a drop below clinically
meaningful thresholds) in HIV-infected patients undergoing ART.
By sparing up to 54% of current laboratory-based testing using a
CD4 count threshold of 200 cells/ml, the implementation of our
method could help focus laboratory-based CD4 count testing
capacity on patients with higher likelihood of CD4 failure. This
work provides the basis for future prospective testing of the
model’s overall safety, cost-effectiveness, and clinical outcomes in
low-resource settings.
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Editors’ Summary
Background. AIDS has killed nearly 30 million people since
1981, and about 34 million people (most of them living in
low- and middle-income countries) are now infected with
HIV, the virus that causes AIDS. HIV destroys immune system
cells (including CD4 cells, a type of lymphocyte and one of
the body’s white blood cell types), leaving infected
individuals susceptible to other infections. Early in the AIDS
epidemic, most HIV-infected people died within ten years of
infection. Then, in 1996, antiretroviral therapy (ART) became
available, and for people living in affluent countries, HIV/
AIDS became a chronic condition. However, ART was
expensive, and for people living in developing countries,
HIV/AIDS remained a fatal illness. In 2003, HIV was declared a
global health emergency, and in 2006, the international
community set itself the target of achieving universal access
to ART by 2010. By the end of 2010, only 6.6 million of the
estimated 15 million people in need of ART in developing
countries were receiving ART.
Why Was This Study Done? One factor that has impeded
progress towards universal ART coverage has been the
limited availability of trained personnel and laboratory
facilities in many developing countries. These resources are
needed to determine when individuals should start ART—
the World Health Organization currently recommends that
people start ART when their CD4 count drops below 350
cells/ml—and to monitor treatment responses over time so
that viral resistance to ART is quickly detected. Although a
total lymphocyte count can be used as a surrogate measure
to decide when to start treatment, repeated CD4 cell counts
are the only way to monitor immunologic responses to
treatment, a level of monitoring that is rarely sustainable in
resource-constrained settings. A method that optimizes
resource allocation by prioritizing who gets tested might
be one way to improve treatment monitoring. In this study,
the researchers applied a new tool for prioritizing laboratory-
based CD4 cell count testing in resource-constrained settings
to patient data that had been previously collected.
What Did the Researchers Do and Find? The researchers
fitted a mixed-effects statistical model to repeated CD4
count measurements from HIV-infected individuals from
seven sites around the world (including some resource-
limited sites). They then used model-derived estimates to
apply a mathematical tool for predicting—from a CD4 count
taken at the start of treatment, and white blood cell counts
and lymphocyte percentage measurements taken later—
whether CD4 counts would be above 200 cells/ml (the
original threshold recommended for ART initiation) and 350
cells/ml (the current recommended threshold) for up to three
years after ART initiation. The tool correctly classified 91.5%
of the CD4 cell counts that were below 200 cells/ml in the
first year of ART. With this threshold, the potential savings in
CD4 testing capacity was 54.3%. With a CD4 count threshold
of 350 cells/ml, the potential savings in testing capacity was
34%. The results over a three-year follow-up were similar.
When applied to six representative HIV-positive individuals,
the tool correctly predicted all the CD4 counts above 200
cells/ml, although some individuals who had a predicted CD4
count of less than 200 cells/ml actually had a CD4 count
above this threshold. Thus, none of these individuals would
have been exposed to an undetected dangerous CD4 count,
but the application of the tool would have saved 57% of the
CD4 laboratory tests done during the first year of ART.
What Do These Findings Mean? These findings support
the use of this new tool—the prediction-based classification
(PBC) algorithm—for predicting a drop in CD4 count below a
clinically meaningful threshold in HIV-infected individuals
receiving ART. Further studies are now needed to
demonstrate the feasibility, clinical effectiveness, and cost-
effectiveness of this approach, to find out whether the tool
can be used over extended periods of time, and to
investigate whether the accuracy of its predictions can be
improved by, for example, adding in periodic CD4 testing.
Provided these studies confirm its early promise, the
researchers suggest that the PBC algorithm could be used
as a ‘‘triage’’ tool to direct available laboratory testing
capacity to high-priority individuals (those likely to have a
dangerously low CD4 count). By optimizing the use of
limited laboratory resources in this and other ways, the PBC
algorithm could therefore help to maintain and expand ART
programs in low- and middle-income countries.
Additional Information. Please access these web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001207.
N Information is available from the US National Institute of
Allergy and Infectious Diseases on HIV infection and AIDS
N NAM/aidsmap provides basic information about HIV/AIDS
and summaries of recent research findings on HIV care and
treatment
N Information is available from Avert, an international AIDS
charity, on many aspects of HIV/AIDS, including informa-
tion on HIV/AIDS treatment and care and on universal
access to AIDS treatment (in English and Spanish)
N The World Health Organization provides information about
universal access to AIDS treatment (in several languages)
N More information about universal access to HIV treatment,
prevention, care, and support is available from UNAIDS
N Patient stories about living with HIV/AIDS are available
through Avert and through the charity website
Healthtalkonline
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